| 產(chǎn)品名稱 | CESS |
|---|---|
| 商品貨號 | B164229 |
| Organism | Homo sapiens, human |
| Tissue | blood |
| Cell Type | lymphoblast |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension |
| Biosafety Level | 2 [Cells Contain HERPESVIRUS]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | myelomonocytic leukemia |
| Age | adult |
| Gender | Male |
| Ethnicity | Caucasian |
| Applications | CESS cells can be used to assay T-cell replacing factor (TRF). |
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | Isolated from the peripheral blood of an adult Caucasian male patient with myelomonocytic leukemia after incubation with Epstein-Barr Virus. |
| Clinical Data | male Caucasian adult |
| Receptor Expression | complement |
| Genes Expressed | immunoglobulin; surface immunoglobulin (sIg+); Epstein-Barr virus (EBV) |
| Cellular Products | immunoglobulin; surface immunoglobulin (sIg+); Epstein-Barr virus (EBV) |
| Comments | The cells are EBNA +.
|
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing | Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 x 105 viable cells/mL. Maintain cultures at a cell concentration between 2 x 105 and 1 x 106 cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation | Complete growth medium supplemented with 5% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X.
|
| Culture Conditions | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| STR Profile | D5S818: 11,12 D13S317: 12 D7S820: 10,12 D16S539: 12 vWA: 16,17 THO1: 7,9.3 Amelogenin: X,Y TPOX: 8,9 CSF1PO: 10,11 |
| Isotype | IgG |
| Name of Depositor | P Ralph |
| Deposited As | Homo sapiens |
| References | Muraguchi A, et al. T cell-replacing factor-(TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J. Immunol. 127: 412-416, 1981. PubMed: 6972960 Miki Y, et al. The requirement for esterase activation in T cell replacing factor (TRF)-induced IgG production in a human B blastoid cell line. J. Immunol. 128: 675-678, 1982. PubMed: 6798119 Kishimoto T, et al. IgG induction in a human B cell line by red cell-mediated microinjection of the cytoplasm from T cell factor-stimulated B cells. J. Immunol. 129: 1367-1371, 1982. PubMed: 6980930 Miki Y, et al. Induction of IgG production in a human monoclonal B lymphoblastoid cell line by a B cell-specific monoclonal antibody. J. Immunol. 129: 1921-1925, 1982. PubMed: 6981668 Bradley TR, et al. Cell lines derived from a human myelomonocytic leukaemia. Br. J. Haematol. 51: 595-604, 1982. PubMed: 6980663 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
